RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 participants will receive o…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:28 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial underway
Disease control OngoingThis study looks at three different drug combinations for women with ovarian, fallopian tube, or primary peritoneal cancer that has returned and is no longer responding to platinum-based chemotherapy. The trial compares a standard chemotherapy drug (pegylated liposomal doxorubici…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:27 UTC
-
New drug combo may offer alternative to chemo for ovarian cancer
Disease control OngoingThis study tested whether the targeted drugs olaparib (alone or with cediranib) work better than standard platinum-based chemo for women with ovarian, fallopian tube, or peritoneal cancer that came back after initial treatment. About 579 women with platinum-sensitive cancer took …
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:26 UTC
-
New hope for recurrent ovarian and endometrial cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called tazemetostat in 62 people whose ovarian or endometrial cancer has returned after previous treatment. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the drug can shrink tumors or stop them from growing f…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study compares two treatments for women with ovarian, fallopian tube, or peritoneal cancer that has come back after initial therapy. One group gets olaparib alone, the other gets olaparib plus tremelimumab. Olaparib blocks cancer cells from repairing themselves, while tremel…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New combo aims to outsmart Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:18 UTC